Clinical trials: Cutaneous Melanoma, Stage II
Melanoma Stage III, Melanoma Stage IV
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT03153085
- Testing
- TBI-1401(HF10), Ipilimumab
- Where
- 12 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Malignant Melanoma
Intratumoral Application of L19IL2 in Patients With Malignant Melanoma
Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.
- Trial name
- NCT01253096
- Testing
- Intratumoral injections of L19IL2
- Where
- 3 sites in Austria, Germany
- Volunteers
- 25 people
- Sponsor
- Philogen S.p.A.
Solid Tumours
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and GSK1120212 in subjects with BRAF V600E/K mutation…
- Trial name
- NCT01928940
- Testing
- dabrafenib, trametinib
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Stage IV Melanoma
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the…
- Trial name
- NCT02990416
- Testing
- A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Virogen Biotechnology Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Melanoma
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer…
- Trial name
- NCT05933577
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 165 sites in United States, Argentina and 24 more
- Volunteers
- 1,089 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Phase II, 2nd Line Melanoma - RAND Monotherapy
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137…
- Trial name
- NCT00612664
- Testing
- Anti-CD137 (4-1BB) (BMS-663513)
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 158 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Uveal Melanoma
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with…
- Trial name
- NCT05415072
- Testing
- DYP688
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Malignant Melanoma, Skin
Intratumoral Administration of L19IL2/L19TNF
This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a.
- Trial name
- NCT02076633
- Testing
- L19IL2+L19TNF
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Philogen S.p.A.
Cancer
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
This is a dose-escalation, Phase I/II, open-label, three-part study. Part 1 is designed to determine the recommended dose and schedule for the orally administered MEK inhibitor trametinib, given together with the CDK4/6 inhibitor…
- Trial name
- NCT02065063
- Testing
- Trametinib, Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Melanoma
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
This research study involves two investigational drugs, an Activator Ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001).
- Trial name
- NCT01397708
- Testing
- INXN-2001, INXN-1001
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alaunos Therapeutics
Melanoma
Trial of pIL-12 Electroporation Malignant Melanoma
This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene…
- Trial name
- IL-12MEL (NCT01502293)
- Testing
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoSec Medical Incorporated
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or…
- Trial name
- NCT01693068
- Testing
- Pimasertib, Dacarbazine
- Where
- 101 sites in United States, Australia and 12 more
- Volunteers
- 194 people
- Sponsor
- EMD Serono
Malignant Melanoma
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients
The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.
- Trial name
- NCT00306566
- Testing
- CYT004-MelQbG10
- Where
- Switzerland
- Sponsor
- Cytos Biotechnology AG
Cutaneous Melanoma
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Randomized, open, Phase II-III study, comparative between treatment with CSF-470 vaccine , allogeneic, irradiated with BCG and molgramostin (rHuGM-CSF) as adjuvants and interferon alfa 2b (IFN-alpha2b) treatment , in stages IIB…
- Trial name
- NCT01729663
- Testing
- CSF470 vaccine, BCG, Molgramostim, interferon alpha 2b
- Where
- Argentina
- Volunteers
- 108 people
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Malignant Melanoma
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
The purpose of the study is to test safety and efficacy of different doses of thymosin alpha 1 (1.6 mg, 3.2 mg, and 6.4 mg) in combination with dacarbazine and with or without Interferon alpha in treating patients affected by…
- Trial name
- NCT00911443
- Testing
- Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg, Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg, Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg
- Where
- 64 sites in France, Germany and 6 more
- Volunteers
- 488 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Stage III or Stage IV Melanoma
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
This study examines the safety of treating patients with advanced stage melanoma with the vaccine CADI-05. In addition, preliminary data regarding the clinical response and immune response will be collected.
- Trial name
- NCT00675727
- Testing
- CADI-05
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cadila Pharnmaceuticals
Melanoma
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
The purpose of the study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel in subjects with Stage III (unresectable) and Stage IV melanoma.
- Trial name
- NCT01009775
- Testing
- YM155, Docetaxel
- Where
- 13 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Astellas Pharma Inc
Malignant Melanoma
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
- Trial name
- NCT00135408
- Testing
- Ipilimumab+ Budesonide
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb